Vaxchora Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The vaxchora market research report is one of a series of new reports that provides vaxchora market statistics, including the vaxchora industry's global market size, regional shares, competitors with a vaxchora market share, detailed vaxchora market segments, market trends and opportunities, and any further data you may need to thrive in the vaxchora industry. This vaxchora market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to rising cholera outbreaks cases, increasing international travel to cholera-endemic regions, rising awareness of cholera risks among travelers, increasing funding for cholera vaccination campaigns, and growing medical tourism industry. Major trends in the forecast period include advancements in vaccine formulation, advancements in oral vaccine, advancements in microbiology and immunology research, and integration of AI for cholera outbreak prediction models.

The increasing incidence of cholera is expected to drive the growth of the vaxchora market. Cholera is an infection caused by the Vibrio cholerae bacterium, leading to severe diarrhea and dehydration, typically transmitted through contaminated food or water. The rise in cholera cases is linked to factors such as inadequate sanitation, lack of clean water access, climate change, and growing population movement to regions where cholera is endemic. Vaxchora helps prevent cholera by stimulating the immune system to produce antibodies against the Vibrio cholerae O1 serogroup, thereby reducing the risk of severe dehydration and diarrhea from cholera infection. For example, in 2023, the World Health Organization reported a 13% increase in cholera cases and a 71% rise in deaths compared to 2022, leading to over 4,000 preventable deaths. Cholera spread to 45 countries in 2023, up from 44 in 2022 and 35 in 2021. Consequently, the growing number of cholera cases is driving demand for Vaxchora.

A key trend in the vaxchora market is the expansion of regional approvals for the vaccine, which aims to increase accessibility and meet the growing demand for cholera prevention in endemic and high-risk areas. Expanded regional approvals contribute to improving public health outcomes by enhancing immunization coverage and addressing the global need for effective cholera prevention. For example, in September 2024, Bavarian Nordic, a biotechnology company based in Denmark, announced the commercial availability of Vaxchora in Canada. This single-dose oral vaccine is approved to protect against cholera and provides protection within 10 days of administration.

In May 2023, Bavarian Nordic A/S acquired a travel vaccine portfolio from Emergent BioSolutions for $270 million. The acquisition includes two marketed vaccines, Vivotif for typhoid fever and Vaxchora for cholera, as well as a Phase III candidate for chikungunya. This acquisition strengthens Bavarian Nordic's position in the travel vaccine market while boosting its research and development capabilities. Emergent BioSolutions, based in the United States, is a biotechnology company that develops vaccines, including Vaxchora.

The key company operating in the vaxchora market is Bavarian Nordic A/S.

North America was the largest region in the vaxchora market in 2024. The regions covered in vaxchora report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vaxchora market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Vaxchora is a vaccine designed to prevent cholera, an infectious disease caused by the bacterium Vibrio cholerae. It is approved for use in individuals aged 2 years and older who are traveling to areas where cholera is prevalent. The vaccine is recommended for adults aged 18 to 64 planning to visit regions where cholera is common. Vaxchora is administered as a single-dose liquid and should be taken 10 days before potential exposure to the bacteria.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary clinical indications for vaxchora include the prevention of cholera and the prevention of gastrointestinal infections caused by Vibrio cholerae. Preventing cholera involves controlling the spread of Vibrio cholerae through vaccination, sanitation, and safe water practices. Vaxchora is an oral vaccine that helps protect individuals traveling to endemic areas by stimulating immunity against Vibrio cholerae. Distribution channels for the vaccine include hospital pharmacies, retail pharmacies, online pharmacies, and travel pharmacies. End users include adults, pediatric patients, and geriatric individuals.

The vaxchora market consists of sales of oral cholera vaccines, vaccine administration supplies, and cold chain equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.